Grifols SA (Grifols) is a speciality pharmaceutical company that develops, manufactures and distributes biological medicines based on plasma-derived proteins. It offers in vitro diagnostics products for the use in clinical and blood bank laboratories; and nutrition products, intravenous solutions and medical devices for use in clinics and hospitals. The company classifies its operations into four divisions, namely, Biopharma, Diagnostic, Bio Supplies, and Others. Grifols offers products and services to healthcare providers in over 100 countries globally.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Grifols’ R&D activities focus on developing products, researching new applications for existing products, and improving manufacturing processes to enhance yields, safety, and efficiency. The company focuses on developing in vitro diagnostic reagents, assays, instrumentation, and software for donor screening. The company supports various business areas such as transfusion medicine, clinical diagnostics, and the recombinant protein business. It also focuses on the delivery of products, integrated technology solutions, and services that enhance safety, quality, and efficiency in operational pharmacy. The company's major technologies include NAT technology and gel agglutination technology. In FY2024, the company spent EUR330.7 million on R&D, which as a percentage of revenue stood at 4.5. As of December 31, 2024, the company had 2,688 patents and patent applications, of which 689 are in the final application process.